Dermapharm Holding SE/€DMP
1D1W1MYTD1Y5YMAX
Capital at risk
About Dermapharm Holding SE
Dermapharm Holding SE is a pharmaceutical company based in Germany, specializing in the development, production, and commercialization of off-patent branded pharmaceuticals. The company focuses on several key product segments, including dermatological and allergy products, vitamins, and food supplements. Established in 1991, Dermapharm has developed a diversified product portfolio with over 900 marketing authorizations. It operates production facilities in Europe and maintains a strong sales presence in Germany and other European countries. The company's strategic positioning is bolstered by its vertically integrated business model, which enables efficient product development and manufacturing processes.
- Ticker
- €DMP
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 3,619
- Headquarters
- Grünwald, Germany
- Website
- ir.dermapharm.de
DMP Metrics
BasicAdvanced
€1.9B
13.66
€2.77
0.85
€0.88
2.32%
Price and volume
Market cap
€1.9B
Beta
0.85
52-week high
€51.60
52-week low
€31.85
Average daily volume
45K
Dividend rate
€0.88
Financial strength
Current ratio
1.712
Quick ratio
0.75
Long term debt to equity
1.932
Total debt to equity
2.193
Dividend payout ratio (TTM)
33.07%
Interest coverage (TTM)
5.48%
Profitability
EBITDA (TTM)
309.649
Gross margin (TTM)
65.41%
Net profit margin (TTM)
12.39%
Operating margin (TTM)
21.06%
Effective tax rate (TTM)
24.50%
Revenue per employee (TTM)
€330,000
Management effectiveness
Return on assets (TTM)
7.11%
Return on equity (TTM)
25.57%
Valuation
Price to earnings (TTM)
13.658
Price to revenue (TTM)
1.693
Price to book
3.48
Price to tangible book (TTM)
-3.44
Price to free cash flow (TTM)
9.268
Free cash flow yield (TTM)
10.79%
Free cash flow per share (TTM)
4.084
Dividend yield (TTM)
2.32%
Forward dividend yield
2.32%
Growth
Revenue change (TTM)
0.40%
Earnings per share change (TTM)
39.03%
3-year revenue growth (CAGR)
1.34%
3-year earnings per share growth (CAGR)
6.63%
3-year dividend per share growth (CAGR)
-5.72%
Bulls say / Bears say
Dermapharm reaffirmed its full-year 2026 revenue guidance of €1.182–1.218 billion and adjusted EBITDA guidance of €331–341 million on June 26, underscoring management’s confidence in its growth strategy (Reuters via Stockopedia).
The high-margin “Branded pharmaceuticals” segment delivered an 11.7% increase in Q1 2026 revenues to €162.9 million, highlighting robust demand for its core portfolio (Investegate).
H1 2026 adjusted EBITDA rose 10.3% to €163.2 million, lifting the adjusted EBITDA margin to 27.6% as cost efficiencies and favourable currency effects enhanced profitability (Investegate).
BaFin has launched a review of Dermapharm’s 2025 financial statements over alleged accounting irregularities, including a misrecorded €63.2 million receivable and inadequate related-party disclosures (Reuters via Marketscreener).
In 2025, Dermapharm’s consolidated revenue fell by 1.3% to €1.2 billion, driven by portfolio optimisation in its parallel import business, highlighting sensitivity to segment adjustments (Reuters).
Q1 2026 consolidated revenue grew only 1.1% year-on-year to €305.8 million, indicating limited top-line momentum outside the branded pharmaceuticals segment (Reuters via Marketscreener).
Data summarised monthly by Lightyear AI. Last updated on 26 Aug 2026.
Upcoming events
No upcoming events
Funds containing DMP
AllGBPEUR
Fund name | Fund size | €DMP weighting |
|---|---|---|
WisdomTree Global Quality Dividend Growth£GGRG | £1.9B | 0.03% |
Vanguard ESG Global All Cap€V3AA | €1.1B | 0.00% |
Vanguard ESG Global All Cap£V3AB | £905M | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.